The Methylation Cycle: MTHFR, Homocysteine, and Methyl Nutrients
How the methylation cycle controls gene expression, mood, detox, and cardiovascular health — and what to do when it isn't working well
Methylation is one of the most fundamental processes in human biochemistry, happening roughly a billion times per second across every cell in your body. It controls which genes are switched on or off, helps make serotonin, dopamine, and melatonin, neutralizes toxins in the liver, and keeps DNA replication accurate. When the process is impaired — often because of a common gene variant called MTHFR — a compound called homocysteine can build up, raising the risk of heart disease, cognitive decline, and pregnancy complications [3][6]. The encouraging part is that targeted B vitamins and a few food-derived compounds can support methylation effectively, regardless of your genetics [1].
How Methylation Works
Methylation means attaching a methyl group — one carbon atom bonded to three hydrogen atoms (-CH3) — to another molecule. This tiny chemical modification can switch a gene on or off, convert one neurotransmitter into another, tag a toxin for liver clearance, or protect a strand of DNA during copying.
The central molecule in the methylation cycle is SAMe (S-adenosylmethionine), sometimes called the body's universal methyl donor. SAMe is produced from the amino acid methionine (found in meat, eggs, fish, and legumes) with the help of a cascade of B-vitamin-dependent enzymes. Once SAMe donates its methyl group to complete a reaction, it becomes homocysteine — a compound that must be recycled back to methionine to keep the cycle going.
The recycling step — and where MTHFR comes in
Recycling homocysteine back to methionine requires two things: vitamin B12 (as methylcobalamin) and active folate (as 5-methyltetrahydrofolate, or 5-MTHF). The enzyme MTHFR (methylenetetrahydrofolate reductase) is responsible for converting dietary folate and synthetic folic acid into 5-MTHF — the only form that works in this recycling step [2].
Roughly 40–60% of people carry at least one copy of the MTHFR C677T variant, which reduces enzyme activity by about 35% per copy. Approximately 10–15% of the population is homozygous (two copies), which can reduce activity by up to 70%. This genetic variant does not automatically cause disease, but it does mean the methylation cycle runs less efficiently, which can result in lower circulating active folate and impaired homocysteine recycling [6].
Why Elevated Homocysteine Matters
When homocysteine is not efficiently recycled, it accumulates. Elevated homocysteine damages the endothelial lining of blood vessels, promotes oxidative stress, impairs nitric oxide signalling, and has been associated with higher risks of cardiovascular disease, stroke, cognitive decline, and miscarriage. A 2022 meta-analysis found that each 5 µmol/L increase in plasma homocysteine is associated with a 22% higher incidence of coronary heart disease [3]. Normal homocysteine is generally considered below 10–12 µmol/L; levels above 15 µmol/L are classified as hyperhomocysteinemia.
Measuring homocysteine is straightforward — a standard fasting blood test — and it is one of the more actionable cardiovascular and neurological risk markers available.
Nutrients That Support Healthy Methylation
Methylated folate (5-MTHF)
The most important intervention for anyone with MTHFR variants is using the active, pre-converted form of folate — 5-MTHF (also marketed as methylfolate or L-methylfolate) — rather than synthetic folic acid. Folic acid requires a functioning MTHFR enzyme to be activated; 5-MTHF bypasses this step entirely and enters the methylation cycle directly [2]. Standard supplementation doses range from 400–1,000 µg/day. Food sources of natural folate (leafy greens, liver, legumes) contain a mix of folate forms that are also more bioavailable than folic acid.
Methylcobalamin (B12)
B12 works alongside 5-MTHF as a direct cofactor in the homocysteine-to-methionine recycling reaction. The methylcobalamin form is preferred over cyanocobalamin for this purpose, as it is the biologically active form used in the methylation cycle. See our vitamin B12 page for food sources and signs of deficiency.
Riboflavin (B2)
MTHFR is a flavoenzyme — it requires riboflavin (B2) as a cofactor. Research shows that riboflavin deficiency compounds the functional impact of the C677T variant. Ensuring adequate riboflavin from dairy, eggs, and organ meats helps the MTHFR enzyme work as well as it can, even with genetic limitations.
Pyridoxal-5-phosphate (active B6)
B6 is required for the transsulfuration pathway, an alternative route for processing excess homocysteine through cysteine and eventually glutathione. It acts as a safety valve when the main recycling route is backed up. Food sources include poultry, fish, potatoes, and bananas.
Trimethylglycine (TMG / betaine)
TMG provides three methyl groups and works through a separate enzyme (BHMT, betaine-homocysteine methyltransferase) that bypasses the folate-and-B12-dependent route entirely. This makes it a useful backup methyl donor — particularly relevant for people with MTHFR variants or very high homocysteine [5]. Beets are the richest dietary source (approximately 127 mg per 100 g), followed by spinach and quinoa. Supplemental doses in research range from 1.5–6 g/day.
Choline
Choline is converted to TMG in the liver, making it another dietary source of methyl groups. Eggs are the most concentrated food source; see our choline page for more.
Practical Considerations
If you know you carry MTHFR C677T variants (genetic testing is widely available through services like 23andMe), consider:
- Replacing standard folic acid supplements with methylated folate (5-MTHF)
- Using methylcobalamin rather than cyanocobalamin for B12
- Eating foods naturally rich in folate and betaine daily (leafy greens, beets, eggs, liver)
- Testing homocysteine levels as a functional methylation marker — many functional medicine practitioners target below 8–10 µmol/L
For most people without known MTHFR variants, a varied diet with adequate B vitamins is sufficient. Methylation support supplements are most warranted for those with confirmed variants, elevated homocysteine, pregnancy planning, or conditions associated with methylation impairment (depression, cardiovascular disease, cognitive decline).
Cross-references: Homocysteine | Folate | Vitamin B12 | Choline | SAMe
Evidence Review
MTHFR prevalence and functional impact
The C677T polymorphism in MTHFR is among the most studied single nucleotide polymorphisms in nutritional genomics. Hou et al. (2023) conducted a case-control study demonstrating that MTHFR C677T homozygosity was associated with significantly higher homocysteine levels and greater burden and severity of both acute myocardial infarction and acute cerebral infarction, supporting its role as a clinically relevant modifiable cardiovascular risk factor [6]. The biochemical mechanism is well-established: the thermolabile TT variant has approximately 30–70% lower enzyme activity than the CC wild-type, depending on riboflavin status and folate supply.
Cardiovascular risk from elevated homocysteine
Wang et al. (2022) conducted a systematic review and meta-analysis of case-control and prospective cohort studies up to October 2021, concluding that homocysteine is an independent risk factor for coronary heart disease with a dose-response relationship: each 5 µmol/L increase in plasma homocysteine corresponds to a 22% increase in CHD incidence [3]. This is consistent with earlier pooled analyses. Causality is supported by Mendelian randomisation studies showing that genetically elevated homocysteine (via MTHFR variants) correlates with increased cardiovascular risk. However, several large intervention trials lowering homocysteine with B vitamins did not significantly reduce major cardiovascular events in people with pre-existing disease, suggesting that lowering homocysteine may be more important as a preventive measure than as treatment after atherosclerosis is established.
5-MTHF versus folic acid: bioavailability and MTHFR
Scaglione and Panzavolta (2014) provided a detailed biochemical analysis distinguishing folic acid (the synthetic, oxidized, monoglutamate form) from the natural reduced folate forms found in food and the biologically active 5-MTHF [2]. Folic acid requires conversion via dihydrofolate reductase and then MTHFR to become 5-MTHF; this pathway is rate-limited in individuals with MTHFR variants. The authors note that high doses of folic acid may result in unmetabolized folic acid entering circulation, with uncertain immunological effects.
Lamers et al. (2006) tested this distinction in a 24-week double-blind RCT with 144 women of childbearing age randomized to 400 µg folic acid, 416 µg [6S]-5-MTHF (equimolar), 208 µg [6S]-5-MTHF, or placebo daily. Red blood cell folate — the primary functional measure of long-term folate status — increased significantly more in the 5-MTHF groups than in the folic acid group, despite the equimolar dose [4]. This finding is particularly important for preconception and pregnancy planning, where folate status directly affects neural tube development.
Carboni (2022) reviewed 12 randomized trials in a systematic narrative review and concluded that 5-MTHF is at least equivalent to folic acid for folate status improvement in the general population and superior in individuals with MTHFR polymorphisms, depression, and certain neurological conditions [1]. The review also notes growing concern that fortification with synthetic folic acid may leave MTHFR-variant individuals underserved despite appearing to receive adequate folate by conventional measurement.
Betaine as an alternative methyl donor
Schwab et al. (2006) conducted a dose-response crossover study in healthy adults using oral betaine at 1.5, 3, and 6 g per day, measuring plasma homocysteine over time [5]. Betaine produced acute, dose-dependent reductions in plasma homocysteine, with 6 g lowering levels by approximately 10–20% within 6 hours of a single dose. The effect was sustained with repeated dosing. Betaine works via betaine-homocysteine methyltransferase (BHMT) in the liver, a folate-independent pathway that is active when the MTHFR-dependent route is compromised. Notably, the authors observed that betaine increased LDL cholesterol in some subjects, an effect worth monitoring if supplementing at higher doses in those with lipid concerns.
Evidence gaps and clinical context
The strongest evidence base for methylation support involves: (1) folate for neural tube defect prevention in pregnancy, where the benefit is unambiguous; (2) B-vitamin lowering of homocysteine as a risk marker; and (3) 5-MTHF superiority over folic acid for individuals with MTHFR variants. Whether correcting elevated homocysteine with B vitamins translates into reductions in hard clinical outcomes (stroke, dementia, myocardial infarction) in otherwise healthy people is less established. Most intervention trials have enrolled subjects with established disease, making it difficult to determine the preventive value. Population studies and genetic evidence (Mendelian randomisation) generally support a causal role for homocysteine in disease risk, which forms the rationale for optimising methylation support as a primary prevention strategy.
References
- Active Folate Versus Folic Acid: The Role of 5-MTHF (Methylfolate) in Human HealthCarboni L. Integrative Medicine (Encinitas), 2022. PubMed 35999905 →
- Folate, folic acid and 5-methyltetrahydrofolate are not the same thingScaglione F, Panzavolta G. Xenobiotica, 2014. PubMed 24494987 →
- Systematic review and meta-analysis of the correlation between plasma homocysteine levels and coronary heart diseaseWang B, Mo X, Wu Z, Guan X. Journal of Thoracic Disease, 2022. PubMed 35399239 →
- Red blood cell folate concentrations increase more after supplementation with [6S]-5-methyltetrahydrofolate than with folic acid in women of childbearing ageLamers Y, Prinz-Langenohl R, Brämswig S, Pietrzik K. American Journal of Clinical Nutrition, 2006. PubMed 16825690 →
- Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humansSchwab U, Törrönen A, Meririnne E, Saarinen M, Alfthan G, Aro A, Uusitupa M. Journal of Nutrition, 2006. PubMed 16365055 →
- MTHFR C677T polymorphism, homocysteine, burden, and location of AMI and ACIHou HM, Qin XJ, Zhao HY. European Review for Medical and Pharmacological Sciences, 2023. PubMed 36876682 →
Transparency
View edit historyEvery change to this page is tracked in version control. If you have conflicting research or think something is wrong, we want to hear about it.